Nektar Therapeutics (NKTR) Net Margin (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Net Margin of 397.33% for Q1 2026, up 4647.0% year-over-year from 8.37% in Q1 2025, and down 22347.08% quarter-over-quarter from 1.77% in Q4 2025.
Nektar Therapeutics (NKTR) Net Margin (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Net Margin history runs 17 years deep, the most recent figure standing at 397.33% for Q1 2026.
- In Q1 2026, Net Margin rose 4647.0% year-over-year to 397.33%; the TTM figure through Mar 2026 stood at 211.63% (down 9267.0% YoY), while the FY2025 annual figure was 219.08%, down 12341.0% from the prior year.
- Net Margin for Q1 2026 stood at 397.33%, down from 1.77% in the prior quarter.
- The five-year high for Net Margin was 109.87% in Q4 2024, with the low at 736.94% in Q2 2022.
- The 5-year median for Net Margin is 249.39% (2023), against an average of 260.98%.
- The sharpest annual moves came in 2022 and 2023: Net Margin tumbled 142303 bps in 2022, then surged 48755 bps in 2023.
- Nektar Therapeutics' Net Margin stood at 91.6% in 2022, then slumped by 292 bps to 176.17% in 2023, then surged by 162 bps to 109.87% in 2024, then tumbled by 102 bps to 1.77% in 2025, then sank by 22347 bps to 397.33% in 2026.
- Business Quant data shows NKTR's Net Margin at 397.33% in Q1 2026, 1.77% in Q4 2025, and 296.76% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn | -397.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -397.33% |
| Dec 31, 2025 | -1.77% |
| Sep 30, 2025 | -296.76% |
| Jun 30, 2025 | -350.85% |
| Mar 31, 2025 | -443.80% |
| Dec 31, 2024 | 109.87% |
| Sep 30, 2024 | -153.61% |
| Jun 30, 2024 | -222.93% |
| Mar 31, 2024 | -170.07% |
| Dec 31, 2023 | -176.17% |
| Sep 30, 2023 | -189.85% |
| Jun 30, 2023 | -249.39% |
| Mar 31, 2023 | -634.52% |
| Dec 31, 2022 | 91.60% |
| Sep 30, 2022 | -249.94% |
| Jun 30, 2022 | -736.94% |
| Mar 31, 2022 | -364.16% |
| Dec 31, 2021 | 1,514.63% |
| Sep 30, 2021 | -520.47% |
| Jun 30, 2021 | -443.06% |